KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Twist Bioscience (TWST) EBT (2017 - 2026)

Twist Bioscience has reported EBT over the past 10 years, most recently at -$44.0 million for Q1 2026.

  • Quarterly EBT fell 12.32% to -$44.0 million in Q1 2026 from the year-ago period, while the trailing twelve-month figure was -$80.5 million through Mar 2026, up 57.79% year-over-year, with the annual reading at -$77.0 million for FY2025, 63.03% up from the prior year.
  • EBT was -$44.0 million for Q1 2026 at Twist Bioscience, down from -$30.3 million in the prior quarter.
  • Over five years, EBT peaked at $20.6 million in Q2 2025 and troughed at -$85.4 million in Q2 2024.
  • The 5-year median for EBT is -$44.0 million (2026), against an average of -$43.2 million.
  • Year-over-year, EBT crashed 60.65% in 2022 and then soared 124.11% in 2025.
  • A 5-year view of EBT shows it stood at -$41.7 million in 2022, then fell by 2.73% to -$42.9 million in 2023, then rose by 26.56% to -$31.5 million in 2024, then grew by 3.95% to -$30.3 million in 2025, then plummeted by 45.36% to -$44.0 million in 2026.
  • Per Business Quant, the three most recent readings for TWST's EBT are -$44.0 million (Q1 2026), -$30.3 million (Q4 2025), and -$26.9 million (Q3 2025).